Gastrointestinal peptides--rôle in pathophysiology and disease
- PMID: 6750831
Gastrointestinal peptides--rôle in pathophysiology and disease
Abstract
Progress in gut hormone research has considerably increased our knowledge in gastrointestinal physiology. However, this knowledge has not yet helped the understanding of common gastrointestinal diseases. A pathophysiological role of gut hormones has been established only for rare conditions This is because the clinical significance of the gut hormones is difficult to evaluate. Morphological and biochemical methods used in classical endocrinology can rarely be applied to gastrointestinal endocrinology because of the special design of the gut hormone system. Also gut hormones and autonomous nervous system overlap in their function. A defect of one system can be compensated by the other. Since the hormone-producing cells of the gut are stimulated by food ingestion, any functional or organic change of the digestive tract will alter gut hormone response. Accordingly, most changes of gut hormone levels are secondary. In some--apparently rare--instances such secondary changes contribute to the symptomatology of a pathological condition. In other instances gut hormone abnormalities mimic common diseases, thus demonstrating the heterogenecity of these conditions. More specific and reliable methods are needed to prove or to exclude the participation of gastrointestinal peptides in the pathogenesis of gastrointestinal disease. Gut peptides are an important link between nutrient entry and metabolism. This is realized by a hormonal gut factor (incretin) which augments glucose-induced insulin release. GIP is the most thoroughly investigated but not the only incretin. In addition, GIP seems to have direct effects on lipid metabolism. This would explain why fat releases more GIP than glucose. Except in the case of the metabolic hormones insulin and glucagon the therapeutic usefulness of gastrointestinal peptides has not yet been established.
Similar articles
-
GIP, incretin and gastrointestinal disease.Dan Med Bull. 1983 Jun;30(4):205-14. Dan Med Bull. 1983. PMID: 6347538 Review. No abstract available.
-
Disturbances of the entero-insular axis.Scand J Gastroenterol Suppl. 1983;82:111-9. Scand J Gastroenterol Suppl. 1983. PMID: 6356314
-
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.Regul Pept. 2005 Jun 15;128(2):125-34. doi: 10.1016/j.regpep.2004.07.019. Regul Pept. 2005. PMID: 15780432 Review.
-
Gastric inhibitory polypeptide.Monogr Endocrinol. 1982;24:III-XI, 1-88. Monogr Endocrinol. 1982. PMID: 6214707 Review. No abstract available.
-
Is glucagon-like peptide 1 an incretin hormone?Diabetologia. 1999 Mar;42(3):373-9. doi: 10.1007/s001250051165. Diabetologia. 1999. PMID: 10096792 Review.
Cited by
-
Increases in intestinal glucose absorption and hepatic glucose uptake elicited by luminal but not vascular glutamine in the jointly perfused small intestine and liver of the rat.Biochem J. 1992 May 1;283 ( Pt 3)(Pt 3):759-65. doi: 10.1042/bj2830759. Biochem J. 1992. PMID: 1590766 Free PMC article.
-
Sample taking problems in measuring actual histamine levels of human gastroduodenal mucosa: specific and general relevance in clinical trials on peptic ulcer pathogenesis and selective proximal vagotomy.Gut. 1985 Nov;26(11):1165-78. doi: 10.1136/gut.26.11.1165. Gut. 1985. PMID: 3905529 Free PMC article. Clinical Trial.
-
Differentiation of gut endoderm in dependence of the notochord.Anat Embryol (Berl). 1987;176(3):337-43. doi: 10.1007/BF00310188. Anat Embryol (Berl). 1987. PMID: 3631534